EGFR and non-small cell lung carcinoma: Non-small cell lung cancer (NSCLC) harboring somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) represents a molecular subgroup of NSCLC requiring treatment with EGFR tyrosine kinase inhibitors (TKIs) [1,2,3,4,5,6,7,8].